Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03643055
Other study ID # 92/08/14
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 3, 2014
Est. completion date September 3, 2024

Study information

Verified date November 2020
Source University Medical Centre Ljubljana
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To assess the diagnostic accuracy of 18F-Fluorocholine PET/CT for the detection of medullary thyroid cancer in patients with primary and recurrent disease.


Description:

Medullary thyroid cancer (MTC) is a relatively rare type of cancer that represents up to 10% of all primary thyroid cancers. It is a neuroendocrine tumour derived from parafollicular C-cells of the thyroid. It occurs either sporadically or in a hereditary form as a component of the type 2 multiple endocrine neoplasia (MEN) syndromes, MEN2A and MEN2B, and the related syndrome, familial MTC (FMTC). Currently, the diagnosis of MTC is suspected based on the results of fine-needle aspiration (FNA) cytology, immunohistochemical analysis and elevated laboratory values of tumour markers calcitonin (Ctn) and carcinoembryonic antigen (CEA). According to the 2015 ATA guidelines, the preoperative imaging workup in all patients should include ultrasound examination of the neck; in selected patients, contrast-enhanced CT of the neck and chest, three-phase contrast-enhanced multi-detector liver CT, or contrast-enhanced MRI of the liver, and axial MRI and bone scintigraphy is also recommended. The curative therapy of choice is surgical removal of the tumour and/or metastases. Nodal metastases are detected in 35-50% and distal metastases in about 15% of patients with primary MTC. Even with currently recommended diagnostic imaging techniques, about 50% of patients have persistent/recurrent disease after surgical treatment. This implies that currently available diagnostic imaging studies are suboptimal for accurate disease staging. New hybrid molecular imaging techniques based on SPECT/CT and especially PET/CT could improve disease detection by visualising pathophysiological processes in vivo. The most studied PET radiopharmaceutical for MTC imaging to date has been 18F-FDOPA, with recent studies focusing also on somatostatin receptor imaging using 68Ga-DOTATATE/TOC/NOC radiotracers. 18F-fluorocholine is a structural analogue of choline. It accumulates in cells with active membrane synthesis and overexpressed intracellular signal transduction, processes that are overactive in benign and malignant neoplasms. 18F-fluorocholine is currently primarily used for prostate cancer imaging. In contrast to radiotracers such as18F-fluorodeoxyglucose (18F-FDG), it is also taken up by well-differentiated neoplasms in which 18F-FDG uptake is unreliable. Similarly to 18F-FDG, 18F-fluorocholine is also known to accumulate in inflamed and infected tissue. However, this limitation could be overcome by performing multi-time-point imaging and using basic kinetic analysis. The working hypothesis is that 18F-fluorocholine might be efficiently taken up by primary MTC tumour as well as loco-regional and distant metastases. The aim of the trial is to investigate the diagnostic accuracy of 18F-fluorocholine PET/CT in comparison to existing imaging modalities (US, CT and MRI).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date September 3, 2024
Est. primary completion date March 3, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with medullary thyroid cancer (sporadic or hereditary form). - Patients with newly diagnosed MTC for primary staging (based on fine needle aspiration cytology results). - Patients with suspicion of MTC recurrence for re-staging (based on biochemical, conventional imaging or clinical examination). - Patients with metastatic MTC on systemic therapy for disease activity assessment. Exclusion Criteria: - Pregnancy. - Patient with any PET/CT-scan exam contraindication (eg. severe claustrophobia).

Study Design


Intervention

Diagnostic Test:
18F-fluorocholine PET/CT
18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.

Locations

Country Name City State
Slovenia Department for nuclear medicine, University medical centre Ljubljana Ljubljana

Sponsors (2)

Lead Sponsor Collaborator
University Medical Centre Ljubljana Institute of Oncology Ljubljana

Country where clinical trial is conducted

Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy in primary medullary thyroid cancer Ability to detect primary medullary thyroid cancer (primary, nodal and metastatic lesions) in correlation with histopathological and/or conventional imaging data. 1 month
Primary Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy in recurrent medullary thyroid cancer Ability to detect recurrent medullary thyroid cancer (nodal and distant metastatic lesions) in correlation with histopathological and/or conventional imaging data. 3 months
Secondary Survival analysis based on the initial PET/CT examination Survival analysis of the time to disease progression or disease recurrence after the initial PET/CT examination. 5 years
Secondary Biochemical/clinical outcome - Ctn levels Normalization/stable elevation/increasing levels of serum Ctn. 5 years
Secondary Biochemical/clinical outcome - CEA levels Normalization/stable elevation/increasing levels of serum CEA. 5 years
Secondary Correlation between tumour metabolic activity and biochemical and histological markers Correlation of tumour metabolic activity with biochemical serum marker levels (Ctn, CEA) and tumour metabolic activity and histological quantitative indexes (eg Ki-67). 1 month
Secondary Modification rate of patient's surgical and medical care after 18F-fluorocholine PET/CT Rate of patients whose management was modified based on the PET/CT imaging findings. 5 years
Secondary Basic kinetic analysis of metabolic activity in the primary tumour, nodal and distant metastases. Ability to differentiate benign and malignant lesions using multiple-time-point imaging. 3 months
See also
  Status Clinical Trial Phase
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06277180 - 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC N/A
Withdrawn NCT04760288 - A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Phase 3
Not yet recruiting NCT06079723 - A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
Recruiting NCT01739634 - The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Phase 1/Phase 2
Recruiting NCT03157128 - A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Phase 1/Phase 2
Completed NCT02856347 - Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin N/A
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04280081 - A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Phase 2
Not yet recruiting NCT06292988 - Predictive Factors for Medullary Thyroid Cancer Aggressiveness
Completed NCT01757470 - Vandetanib Risk Minimisation Effectiveness N/A
Recruiting NCT05830500 - Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma Phase 4
Recruiting NCT03899792 - A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Phase 1/Phase 2
Recruiting NCT01660984 - Natural History Study of Children and Adults With Medullary Thyroid Cancer
Withdrawn NCT03838692 - Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer Phase 2
Terminated NCT02363647 - Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer N/A
Terminated NCT00582712 - An Initial Study of Lithium in Patients With Medullary Thyroid Cancer Phase 2
Recruiting NCT06141369 - Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) N/A
Completed NCT06243965 - Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
Active, not recruiting NCT01298323 - Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment Phase 3